NASDAQ$VRNA

Verona Pharma plc · Q1 2025 earnings

Q1 2025 earnings · · Before market open · Investor relations

Briefing

Verona Pharma reported Q1 2025 revenue of $76.3M, a net loss of $16.3M, diluted EPS of $(0.02).

For Q1 2025, Verona Pharma reported Revenue was $76.3M, net loss was $16.3M, diluted EPS was $-0.02. Management discusses operating trends, liquidity, and outlook in the quarterly filing.

  • Revenue $76.3M for Q1 2025.
  • Net loss $16.3M.
  • Diluted EPS $-0.02.

Headline financials

Total Revenue

$76.3M

Previous: $0.00
EPS (adj)

-$0.02

Previous: -$0.32+93.8%
Prescriptions Filled

25.0K

No prior period
New Patient Starts Growth

25.0%

No prior period
Refills Representation

60.0%

No prior period
Prescribers Growth

50.0%

No prior period
Tier 1 HCP Prescribers

60.0%

No prior period
HCPs Prescribing >20 Patients

425

No prior period
Capital Expenditures

-$535K

Previous: $16K-3443.8%
Net Income

-$16.3M

Previous: -$25.8M+36.7%
Operating Income

-$10.3M

Previous: -$27.2M+62.1%

Revenue & EPS history

Verona Pharma · Revenue · Quarterly

$76.3M

Q1 2025
Beat estimate in 3 of 7 quarters(43%)
ActualEstimate

Forward guidance

Management emphasizes path to profitability, liquidity, and cost discipline.

Tailwinds

  • Operating initiatives and strategic partnerships.
  • Cash runway and restructuring where applicable.

Headwinds

  • Operating losses and financing needs.
  • Macro and competitive uncertainty.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 7 quarterly earnings reports · overlaid with Q1 2025

Historical avgQ1 2025

+3.3%

Avg return

Earnings day

+7.2%

Avg return

5 days after

+5.6%

Avg return

30 days after

48%

12 / 25 earnings

Positive

+56.8%

Q2 2022

Best reaction

-14.7%

Q4 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025
Q3 2025
Q2 2025-0.0%-0.1%+0.9%
Q1 2025+6.4%+5.6%+12.5%
Q4 2024+5.7%+6.4%+1.5%
Q3 2024+9.7%+10.2%+14.0%
Q2 2024+15.8%+36.5%+35.1%
Q1 2024-0.2%-6.8%-18.4%
Q4 2023+5.4%-1.1%-6.4%
Q3 2023+7.6%
Q2 2023-3.4%
Q1 2023+7.1%
Q4 2022-8.5%
Q3 2022-5.8%
Q2 2022+56.8%
Q1 2022+3.8%
Q4 2021-1.1%
Q3 2021-1.7%
Q2 2021+3.9%
Q1 2021-4.4%
Q4 2020-0.1%
Q2 2020+10.3%
Q4 2019-14.7%
Q4 2018-3.3%
Q3 2018+2.1%
Q4 2017-3.5%
Q3 2017-4.2%
Q4 2016
Q3 2016
Q2 2016
Q4 2015
Q4 2014
Q4 2013
Q4 2012

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro